UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Nanogen, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $.001 per Share
--------------------------------------------------------------------------------
(Title of Class of Securities)
630075 10 9
--------------------------------------------------------------------------------
(CUSIP Number)
June 29, 2000
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
/ / Rule 13d-1(b)
/X/ Rule 13d-1(c)
/ / Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
-2-
--------------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Elan Pharmaceutical Investments II, Ltd.
--------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(See Instructions) (a)
(b)
--------------------------------------------------------------------------------
3. SEC Use Only
--------------------------------------------------------------------------------
4. Citizenship or Place of Organization
Bermuda
--------------------------------------------------------------------------------
5. Sole Voting Power
1,287,878
-----------------------------------------------------
Number of 6. Shared Voting Power
Shares
Beneficially 0
-----------------------------------------------------
Owned by Each 7. Sole Dispositive Power
Reporting
Person With: 1,287,878
-----------------------------------------------------
8. Shared Dispositive Power
0
--------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
1,287,878
--------------------------------------------------------------------------------
10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)
/ /
--------------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (9)
5.3%
--------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions)
CO
-3-
Item 1(a). Name of Issuer:
Nanogen, Inc.
Item 1(b). Address of Issuer's Principal Executive Offices:
10398 Pacific Center Court, San Diego, CA 92121
Item 2(a). Name of Person Filing:
This statement is filed on behalf of Elan Pharmaceutical Investments
II, Ltd. (the "Reporting Person")
Item 2(b). Address of Principal Business Office:
Elan Pharmaceutical Investments II, Ltd.
Clarendon House
Church Street
Hamilton, Bermuda
Item 2(c). Citizenship:
Elan Pharmaceutical Investments II, Ltd. is a Bermuda exempted
limited liability company
Item 2(d). Title of Class of Securities:
Common Stock, par value $.001 per share (the "Shares")
Item 2(e). CUSIP Number:
630075 10 9
Item 3. If this statement is filed pursuant to ss.ss.240.13d-1(b) or
240.13d-2(b) or (c), check whether the person is a:
This Item 3 is not applicable
Item 4. Ownership:
(a) Amount beneficially owned: 1,287,878
(b) Percent of class: 5.3%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 1,287,878
(ii) shared power to vote or to direct
the vote: 0
(iii) sole power to dispose or to direct
the disposition of: 1,287,878
(iv) shared power to dispose or to direct the disposition of: 0
-4-
Item 5. Ownership of Five Percent or Less of a Class:
Not Applicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person:
Not Applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported on by the Parent Holding
Company or Control Person:
Not Applicable
Item 8. Identification and Classification of Members of the Group:
Not Applicable
Item 9. Notice of Dissolution of Group:
Not Applicable
Item 10. Certifications:
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or influencing
the control of the issuer of the securities and were not acquired and
are not held in connection with or as a participant in any transaction
having that purpose or effect.
-5-
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: February 17, 2004
ELAN PHARMACEUTICAL INVESTMENTS II, LTD.
By: /s/ Kevin Insley
----------------------------------
Name: Kevin Insley
Title: Vice President